Terms such as ‘copycats’ and ‘knock-offs’ are inaccurate and misleading, say drugmakers. We ask therefore how industry and the media should refer to biosimilar products?
Bespak has launched an auto-injector designed to deliver higher viscosity drug formulations.
Samsung Bioepis has contracted Catalent to provide fill finish services for its Enbrel (etanercept) biosimilar, Benepali.
Tot Biopharm has started work on a second monoclonal antibody (mAb) drug production plant at China’s Suzhou Industrial Park.
Merck has completed the expansion of its biologics API manufacturing facility in Madrid, Spain increasing production capacity by 50%.
Pfizer’s Inflectra will become the first monoclonal antibody biosimilar available in the US when it is launched next month.